YD Bio

YD Bio P/CF

The P/CF (Price-to-Cash-Flow Ratio) of YD Bio (YDES) as of Oct 29, 2026 is -78.04. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -280.27 — a change of -72.16% (higher).

P/CF

-78.04

YoY

-72.16%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of YD Bio is 2025 -78.04 . P/CF (Price-to-Cash-Flow Ratio) of YD Bio was 2024 -280.27 . It decreases by -72.16% higher compared to the previous year.

The YD Bio P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2020
-2,029.81 USD
Jan 1, 2021
-747.82 USD
Jan 1, 2022
-170.31 USD
Jan 1, 2023
-9,249.69 USD
Jan 1, 2024
-280.27 USD
Jan 1, 2025
-78.04 USD
The YD Bio P/CF history
YEARP/CFYoY
-78.04-72.16%
-280.27-96.97%
-9,249.69+5,331.00%
-170.31-77.23%
-747.82-63.16%
-2,029.81—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

YD Bio Stock analysis

What does YD Bio do? YD Bio Ltd is a Taiwan-based company focused on early cancer detection tools, ophthalmologic products for dry eye conditions, and exosome-based therapeutics for complex diseases. The company generates revenue through its core areas of non-invasive cancer detection solutions, dry eye treatment products, and exosome-based therapies, targeting healthcare providers and patients seeking advanced medical solutions. Its products are designed to improve patient outcomes and quality of life by offering accessible diagnostic and therapeutic options in the healthcare sector. The company’s business model emphasizes integrating cutting-edge science with accessible solutions, positioning itself as a provider of transformative healthcare innovations. By developing non-invasive diagnostic tools for early cancer detection, specialized ophthalmologic treatments, and next-generation cell therapies, YD Bio serves medical professionals and patients globally. Its focus on pioneering solutions aligns with the growing demand for early diagnosis and advanced treatment options in the healthcare industry. YD Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about YD Bio stock

P/CF (Price-to-Cash-Flow Ratio) of YD Bio is -78.04 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of YD Bio changed from -280.27 to -78.04, representing a -72.16% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) YD Bio since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s YD Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — YD Bio

All Key Metrics — YD Bio